Semaglutide
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is a drug used to treat type 2 diabetes and reduce obesity.  It was developed by Novo Nordisk in 2012.  It was approved for use in America in 2017.  It was approved in Europe in 2022  and in the National Health Service in 2023.